Showing results (11-20 of 51) with videos related to
Sort By:
Pageof 6
Heart (British Cardiac Society)|October 5, 2010
Prehospital triple antiplatelet therapy in patients with acute ST elevation myocardial infarction leads to better platelet aggregation inhibition and clinical outcome than dual antiplatelet therapyJaap Jan J Smit, Jochem W van Werkum, Jurrien ten Berg, et al.Clinical Cardiology|August 8, 2021
Extended dual antiplatelet therapy with ticagrelor 60 mg in patients with prior myocardial infarction: The design of ALETHEIA, a multi-country observational studyEva Lesén, Christopher Hewitt, Evangelos Giannitsis, et al.JAMA Cardiology|March 9, 2017
One-Year Mortality for Bivalirudin vs Heparins Plus Optional Glycoprotein IIb/IIIa Inhibitor Treatment Started in the Ambulance for ST-Segment Elevation Myocardial Infarction: A Secondary Analysis of the EUROMAX Randomized Clinical TrialEnrico Fabris, Sinem Kilic, Arnoud W J Van't Hof, et al.European Heart Journal. Acute Cardiovascular Care|March 12, 2026
Managing Bleeds on Anticoagulant therapy: A Practical Guide for CliniciansMattia Galli, Beatrice Simeone, Jurrien Ten Berg, et al.JACC. Cardiovascular Interventions|May 7, 2016
Impact of Access Site on Bleeding and Ischemic Events in Patients With Non-ST-Segment Elevation Myocardial Infarction Treated With Prasugrel: The ACCOAST Access SubstudyItalo Porto, Leonardo Bolognese, Dariusz Dudek, et al.Heart (British Cardiac Society)|September 1, 2019
Alcohol septal ablation in patients with severe septal hypertrophyJosef Veselka, Morten Jensen, Max Liebregts, et al.Journal of the American College of Cardiology|December 20, 2014
Effect of prasugrel pre-treatment strategy in patients undergoing percutaneous coronary intervention for NSTEMI: the ACCOAST-PCI studyGilles Montalescot, Jean-Philippe Collet, Patrick Ecollan, et al.Journal of the American College of Cardiology|October 23, 2012
Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trialDavid Erlinge, Jurrien Ten Berg, David Foley, et al.European Heart Journal|May 23, 2014
Bivalirudin is superior to heparins alone with bailout GP IIb/IIIa inhibitors in patients with ST-segment elevation myocardial infarction transported emergently for primary percutaneous coronary intervention: a pre-specified analysis from the EUROMAX trialUwe Zeymer, Arnoud van 't Hof, Jennifer Adgey, et al.Journal of the American College of Cardiology|July 15, 2026
Aspirin Withdrawal in Patients With Coronary Artery DiseaseMattia Galli, Davide Capodanno, Jurrien Ten Berg, et al.Pageof 6